Prognostic Assay for Determining T Cell Response to Hla Antigens and Use Thereof in Field of Tissue Transplantation
The invention provides an in vitro method of determining whether an individual is at risk of, or undergoing, graft damage or rejection of immune origin and/or damage of immune origin to non-graft tissue using polypeptides derived from a major histocompatibility complex (MHC) class I human leukocyte antigen (HLA), such as HLA-A2, and derivatives or analogues thereof.
BALL SIMON [GB]
Type of Offer:
« More Genetics Patents